These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 17987008)

  • 1. New law gives FDA more influence to monitor drug safety.
    Wadman M
    Nat Med; 2007 Nov; 13(11):1269. PubMed ID: 17987008
    [No Abstract]   [Full Text] [Related]  

  • 2. Reforms on drug safety.
    Nature; 2006 Sep; 443(7110):372. PubMed ID: 17006474
    [No Abstract]   [Full Text] [Related]  

  • 3. Conflict between FDA and medicine inevitable.
    Wholey MH; Haller JD
    Diagn Imaging (San Franc); 1995 Oct; 17(10):41-8, 87. PubMed ID: 10159849
    [No Abstract]   [Full Text] [Related]  

  • 4. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.
    Mathis LL; Iyasu S
    Clin Pharmacol Ther; 2007 Aug; 82(2):133-4. PubMed ID: 17632537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
    Kesselheim AS; Mello MM
    Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
    DerGurahian J
    Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
    [No Abstract]   [Full Text] [Related]  

  • 8. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
    Shea LL; Hanson A; Guglielmetti TM; Levy K
    Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
    [No Abstract]   [Full Text] [Related]  

  • 9. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation.
    Struve CT
    Yale J Health Policy Law Ethics; 2005; 5(2):587-669. PubMed ID: 16052895
    [No Abstract]   [Full Text] [Related]  

  • 10. An overview of FDA medical device regulation as it relates to deep brain stimulation devices.
    Peña C; Bowsher K; Costello A; De Luca R; Doll S; Li K; Schroeder M; Stevens T
    IEEE Trans Neural Syst Rehabil Eng; 2007 Sep; 15(3):421-4. PubMed ID: 17894274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug safety and drug efficacy: two sides of the same coin.
    Young RC; Friedman MA; Schilsky RL; Sigal EV
    Clin Cancer Res; 2007 May; 13(9):2533-4. PubMed ID: 17473179
    [No Abstract]   [Full Text] [Related]  

  • 12. Mandatory post marketing studies.
    Somberg J
    Am J Ther; 2007; 14(4):321. PubMed ID: 17667203
    [No Abstract]   [Full Text] [Related]  

  • 13. US Senate passes FDA Revitalization Act.
    Guthrie P
    CMAJ; 2007 Jul; 177(1):23. PubMed ID: 17606930
    [No Abstract]   [Full Text] [Related]  

  • 14. A proposal for financing postmarketing drug safety studies by augmenting FDA user fees.
    Carpenter D
    Health Aff (Millwood); 2005; Suppl Web Exclusives():W5-469-80. PubMed ID: 16234281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The FDA animal efficacy rule and biodefense.
    Gronvall GK; Trent D; Borio L; Brey R; Nagao L;
    Nat Biotechnol; 2007 Oct; 25(10):1084-7. PubMed ID: 17921984
    [No Abstract]   [Full Text] [Related]  

  • 16. Recalls. FDA, industry cooperate to protect consumers.
    Nordenberg T
    FDA Consum; 1995 Oct; 29(8):24-7. PubMed ID: 10151838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The marketplace can't give us the drug safety data we need.
    Avorn J
    MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
    [No Abstract]   [Full Text] [Related]  

  • 18. Leavitt: reforms will improve oversight and openness at FDA.
    FDA Consum; 2005; 39(3):37. PubMed ID: 16127819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ORA's role at FDA headquarters and in the field for product recalls.
    Whetstone SN
    Food Drug Law J; 1998; 53(3):513-6. PubMed ID: 10346723
    [No Abstract]   [Full Text] [Related]  

  • 20. New FDA reporting rule means new concerns.
    Healthc Hazard Mater Manage; 1996 Mar; 9(6):1-4. PubMed ID: 10155771
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.